Received by email:

File: NEWS RELEASE.T. NOV.16.2016.pdf

            CSE:MDM          FSE:2M0      OTCQB:MRPHF
                    Kelowna, British Columbia
          info@marapharm.com Telephone: 778-583-4476




News Release
Nov 16, 2016 Marapharm Ventures Inc. announces an
agreement to acquire assets in California

Kelowna, British Columbia, Canada   November 16, 2016
Marapharm symbols: Canada - CSE:MDM / Germany -
FSE:2M0 / United States - OTCQB:MRPHF

Marapharm Ventures Inc. ("Marapharm") announces that it has
entered into an agreement to purchase an industrial facility in
southern California and three (3) medical marijuana licenses for
manufacturing, cultivation, and retail uses. The land size is
40,510 square feet and the existing building size is 6,875 square
feet, with a 19-foot-ceiling clearance, for a purchase price of $3.2
million USD, based on $450 USD per square foot for the building
and $65 USD per square foot for the land. The yard area is
paved and suitable for greenhouse growing. The purchase is
subject to, and contingent upon, completion of satisfactory due
diligence, including background checks, and closing
documentation for the issuances of the three (3) licenses to
Marapharm within 120 days, with the closing to take place 120
days from the removal of contingencies.
"We are really excited to have such a prize property as well as
three licenses, and to be in the California market. The 'Yes' vote
in California is significant for a number of reasons: (i) California, if
it were a stand-alone state, would be the 6th largest economy in
 the world, with a population of 40 million people, and (ii) this
decision means the entire West Coast of the United States has
legalized recreational marijuana. Once Canada is legal, the West
Coast all the way from Mexico to Alaska will be legal, so the
opportunity is huge," says Linda Sampson, Marapharm CEO.

ABOUT MARAPHARM VENTURES INC.
www.marapharm.com
Marapharm has 300,000 square feet of medical marijuana
licenses, land, and facilities in WA and NV and, about two and a
half years ago, Marapharm applied in Canada to Health Canada
for a MMPR (Production and Sales) license, having since passed
the necessary security clearances. The application is currently in
the in-depth screening process. In September 2016, Health
Canada contacted Marapharm with a provision to amend its
application to allow for the new regulations, known as ACMPR.

Additional information on the operations or financial results of
Marapharm are included in reports on file with applicable
securities regulatory authorities and may be accessed through
the CSE website (www.thecse.com), the OTC website
(www.otcmarkets.com) and Sedar website
(www.sedar.com) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION:
www.marapharm.com or Linda Sampson, CEO, 778-583-4476
info@marapharm.com

STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQBtrademark has approved nor
disapproved the contents of this press release. Neither the
CSE, the FSE nor the OTCQBtrademark accepts responsibility for the
adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute
forward looking statements. The use of any of the words
"anticipate", "continue", "estimate", "expect", `may", "will",
"project", "should", `believe", and similar expressions are
 intended to identify forward-looking statements. These
statements involve known and unknown risks, uncertainties and
other factors that may cause actual results or events to differ
materially from those anticipated in such forward-looking
statements are based on reasonable assumption but no
assurance can be given that these expectations will prove to be
correct and the forward-looking statements included in this news
release should not be unduly relied upon.